Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

Summary

Subjects achieving a clinical response in study OX4218s with a biomarker reduction or symptom response are eligible to enroll in this rollover study to continue once every three weeks fosbretabulin infusions for up to one year.

Timeline

Start

2014-12

Primary completion

2016-08

Completion

2016-08

Drugs

Indications